Novartis AG - ADR

NVS

$89.42

+5.4% last 12 months

Ken Fisher Holding value: $972 Million Jim Simons Holding value: $302 Million Chris Davis Holding value: $2.92 Million Ken Griffin Holding value: $384 Thousand Jeremy Grantham Holding value: $313 Thousand Steven Cohen Holding value: $0 Mario Gabelli Holding value: $0 Tom Gayner Holding value: $0 Tom Russo Holding value: $0

Market Cap

$216 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$76.15 - $94.26

The lowest and highest price in the last 52 weeks.

Price-Earnings Ratio

8.92x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$3.33 (3.75%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to
Market
Industry
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $216 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt. $228 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. $3.33 (3.75%)
1 Year Return Profit or loss of share price change plus dividend yield. +9.1%
52-Week High Highest share price in the last 52 weeks. $94.26
52-Week Low Lowest share price in the last 52 weeks. $76.15
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return. 0.33
Outstanding Shares The number of shares the company has issued and are held by stockholders. 2.43 Billion
Avg 30 Day Volume The number of shares traded in the last 30 days. 2.75 Million

Valuation

Compare to
Market
Industry
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 8.92
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 112.72
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value. $10.73
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 4.26
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 3.58
Enterprise Value to Revenue Enterprise value divided by revenue 4.31
Enterprise Value to EBIT Enterprise Value divided by EBIT 8.15
Total Debt to Enterprise Value Total debt divided by enterprise value 0.14
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. 0.51

Profitability

Compare to
Market
Industry
Revenue Revenue is the sum of all cash flow into the company. $53 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services. $37.3 Billion
EBIT Earnings before tax and interest payments. $28 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue. $24.2 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. 45.63%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. +7.9%
Return on Equity Equity divided by market cap. 39.3%
Return on Assets Indicates a company's profitability in relation to its total assets. 19.31%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. 29.36%

Insider trades

No purchases

No sells

No purchases

No sells

No purchases

No sells

No purchases

No sells

Q3 2021 Q4 2021 Q1 2022 Q2 2022

About Novartis AG - ADR

CEO: Vasant Narasimhan

Industry: Pharmaceuticals: Major

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Similar stocks

Merck & Co Inc
Merck & Co Inc
Pfizer Inc.
Pfizer Inc.
Johnson & Johnson
Johnson & Johnson
Sanofi - ADR
Sanofi - ADR
Glaxosmithkline plc - ADR
Glaxosmithkline plc - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Teva- Pharmaceutical Industries Ltd. - ADR
Abbott Laboratories
Abbott Laboratories
Bayer AG - ADR
Bayer AG - ADR
Astrazeneca plc - ADR
Astrazeneca plc - ADR

News

Novartis'' Cosentyx gets EMA panel nod for expanded use in certain types of arthritis

Novartis'' Cosentyx gets EMA panel nod for expanded use in certain types of arthritis

A committee of the European Medicines Agency ((EMA)) recommended the approval for expanded use of Novartis'' (NVS) drug Cosentyx.The EMA''s Committee for Med...

Seeking Alpha Seeking Alpha, 2 days ago
Auto-injectors Market Will Generate Massive Growth 2022-2028 | Pfizer, Mylan N.V., Novartis International AG

Auto-injectors Market Will Generate Massive Growth 2022-2028 | Pfizer, Mylan N.V., Novartis International AG

CMI has recently updated the Global Auto-injectors Market research report gives the knowledge of all the above factors with transparent, wide-ranging, and su...

OpenPR OpenPR, 4 days ago
Digital Biomarker Market Growth USD 22360 million by 2028: Latest Trends, Industry Dynamics, Size, Share, Top Key Players Analysis | Research by Absolute Reports

Digital Biomarker Market Growth USD 22360 million by 2028: Latest Trends, Industry Dynamics, Size, Share, Top Key Players Analysis | Research by Absolute Reports

Pune, May 13, 2022 (GLOBE NEWSWIRE) -- Researcher''s, " Digital Biomarker Market 2022 " report provides comprehensive insights about top companies and main c...

Benzinga Benzinga, 9 days ago
GlaxoSmithKline PLC – Consensus Indicates Potential 15.4% Upside

GlaxoSmithKline PLC – Consensus Indicates Potential 15.4% Upside

GlaxoSmithKline PLC found using ticker (GSK) now have 3 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between t...

DirectorsTalk DirectorsTalk, 11 days ago
Never miss a trade
To improve your user experience we use cookies.